Eagle Pharmaceuticals suffered a GAAP loss of $3.127 million in 6 months of 2020, compared to a profit of $15.698 million in the previous year. Revenues decreased by 17.4% to $87,958 million compared to $106,487 million a year earlier.
Eagle Pharmaceuticals suffered a GAAP loss of $3.127 million in 6 months of 2020, compared to a profit of $15.698 million in the previous year. Revenues decreased by 17.4% to $87,958 million compared to $106,487 million a year earlier. 
investor.eagleus.com
English (US) 